Phase III ARASENS of darolutamide plus ADT and docetaxel demonstrates consistent OS benefits across various patient segments in metastatic hormone?sensitive prostate cancer

New late─breaking data from the pivotal phase III ARASENS trial confirm consistent overall survival (OS) benefits of darolutamide plus androgen deprivation therapy (ADT) and docetaxel in patients with